Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398705 | 0.86 | RAB9A (0.39) | RAB9ANPC1POLBOPRK1KDM4E | |
| SCHEMBL4396932 | 0.84 | ADORA3 (0.44) | ADORA3ADORA2AADORA1RAB9ANPC1 | |
| SCHEMBL4401713 | 0.84 | GRM5 (0.39) | RAB9ANPC1POLBKDM4ETP53 | |
| SCHEMBL4396398 | 0.82 | P2RY14 (0.49) | RAB9ANPC1P2RY14POLBMEN1 | |
| SCHEMBL4396487 | 0.78 | KMT2A (0.40) | ADORA3ADORA2AADORA1POLBKMT2A | |
| SCHEMBL4396840 | 0.76 | P2RY14 (0.48) | ADORA3ADORA2AADORA1RAB9ANPC1 | |
| SCHEMBL4400724 | 0.75 | P2RY14 (0.49) | ADORA3ADORA2AADORA1RAB9ANPC1 | |
| SCHEMBL4398483 | 0.73 | NPC1 (0.42) | ADORA3ADORA2AADORA1RAB9ANPC1 | |
| SCHEMBL4794609 | 0.73 | MAPT (0.43) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4391749 | 0.72 | RAB9A (0.43) | ADORA3ADORA2AADORA1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| CN-101252935-A | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions containing them, and methods of their use | LEXICON GENETICS INC (US) | 2008-08-27 | — | — | CN | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | ADORA3 570/4885ADORA2A 458/4885ADORA1 309/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | ADORA3 781/4885ADORA2A 286/4885ADORA1 683/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | ADORA3 1476/4885ADORA2A 570/4885ADORA1 491/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | ADORA3 3654/4885ADORA2A 2936/4885ADORA1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.